Literature DB >> 19896446

Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.

Nicolas Sabarth1, M Keith Howard, Helga Savidis-Dacho, André van Maurik, P Noel Barrett, Otfried Kistner.   

Abstract

Preparation for an H5N1 influenza pandemic in humans may involve priming the population with a vaccine produced from an existing, available H5N1 strain. We have used a mouse challenge model to compare the immunogenicity and efficacy of inactivated, Vero cell-derived, whole virus H5N1 vaccines in single immunization and homologous or heterologous prime-boost regimes. A single immunization was sufficient to protect against a lethal challenge with strains from matched and unmatched H5N1 clades. Homologous and heterologous prime-boost regimes induced cross-neutralizing antibodies and cross-protection against representative viruses of H5N1 clade 1, clade 2.1, clade 2.2 and clade 2.3. Moreover, the results indicate that heterologous prime-boost immunization regimes might broaden the specificity of the anti-H5N1 antibody response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896446     DOI: 10.1016/j.vaccine.2009.10.105

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.

Authors:  Felix W Santiago; Theresa Fitzgerald; John J Treanor; David J Topham
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

Review 2.  A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

3.  Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.

Authors:  Mario M Alvarez; Felipe López-Pacheco; José M Aguilar-Yañez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio García-Echauri; Pamela Freiden; Stacey Schultz-Cherry; Manuel I Zertuche-Guerra; David Bulnes-Abundis; Johari Salgado-Gallegos; Leticia Elizondo-Montemayor; Martín Hernández-Torre
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

4.  Molecular recognition of human ephrinB2 cell surface receptor by an emergent African henipavirus.

Authors:  Benhur Lee; Olivier Pernet; Asim A Ahmed; Antra Zeltina; Shannon M Beaty; Thomas A Bowden
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

5.  Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus.

Authors:  Heng Ding; Cheguo Tsai; Ramona Alikiiteaga Gutiérrez; Fan Zhou; Philippe Buchy; Vincent Deubel; Paul Zhou
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

6.  Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines.

Authors:  Shih-Chang Lin; Ming-Hsi Huang; Pei-Chun Tsou; Li-Min Huang; Pele Chong; Suh-Chin Wu
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

7.  The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.

Authors:  Sung-Hsi Wei; Ming-Tsan Liu; Yao-Chou Tsai; Chung-Hsin Liao; Chih-Ming Chen; Wei-Yao Wang; Yi-Lung Huang; Feng-Yee Chang; Pesus Chou
Journal:  BMC Infect Dis       Date:  2014-11-14       Impact factor: 3.090

8.  Comparative Evaluation of T-Cell Immune Response to BTV Infection in Sheep Vaccinated with Pentavalent BTV Vaccine When Compared to Un-Vaccinated Animals.

Authors:  Molalegne Bitew; Chintu Ravishankar; Soumendu Chakravarti; Gaurav Kumar Sharma; Sukdeb Nandi
Journal:  Vet Med Int       Date:  2019-12-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.